Positron Corporation (OTCBB:POSC)(the “Company”), a cardiac molecular imaging solutions company, announced today that the United States Food and Drug Administration (FDA) has approved Neusoft Positron Medical Systems 510(k) submission for its Attrius™ Positron Emission Tomography (PET) scanner product line developed by the Company and its joint venture with Neusoft Medical Systems based in Shenyang, China. Positron’s Attrius™ product line was developed to provide physicians a state of the art cardiac PET molecular imaging system. The AttriusTM scanner comes complete with a feature set designed specifically for cardiac perfusion imaging such as a coronary artery disease software suite that includes; mercator

More...